Loading...
Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck
Beck, Tim N. Kaczmar, John Kaczmar Handorf, Elizabeth A. Nikonova, Anna Dubyk, Cara Peri, Suraj Lango ,Miriam Miriam Ridge, John A. Serebriiskii, Ilya G. Burtness, Barbara A.
Beck, Tim N.
Kaczmar, John Kaczmar
Handorf, Elizabeth A.
Nikonova, Anna
Dubyk, Cara
Peri, Suraj
Lango ,Miriam Miriam
Ridge, John A.
Serebriiskii, Ilya G.
Burtness, Barbara A.
Citations
Altmetric:
Genre
Journal article
Date
2015-05-29
Advisor
Committee member
Department
Cancer and Cellular Biology
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.18632/oncotarget.4321
Abstract
Locally advanced squamous cell carcinoma of the head and neck (SCCHN) that is not associated with human papillomavirus (HPV) has a poor prognosis in contrast to HPV-positive disease. To better understand the importance of RB1 activity in HPV-negative SCCHN, we investigated the prognostic value of inhibitory CDK4/6 phosphorylation of RB1 on threonine 356 (T356) in archival HPV-negative tumor specimens from patients who underwent surgical resection and adjuvant radiation. We benchmarked pT356RB1 to total RB1, Ki67, pT202/Y204ERK1/2, and TP53, as quantified by automatic quantitative analysis (AQUA), and correlated protein expression with tumor stage and grade. High expression of pT356RB1 but not total RB1 predicted reduced overall survival (OS; P = 0.0295), indicating the potential relevance of post-translational phosphorylation. Paired analysis of The Cancer Genome Atlas (TCGA) data for regulators of this RB1 phosphorylation identified loss or truncating mutation of negative regulator CDKN2A (p16) and elevated expression of the CDK4/6 activator CCND1 (cyclin D) as also predicting poor survival. Given that CDK4/6 inhibitors have been most effective in the context of functional RB1 and low expression or deletion of p16 in other tumor types, these data suggest such agents may merit evaluation in HPV-negative SCCHN, specifically in cases associated with high pT356RB1
Description
Citation
Beck TN, Kaczmar JK, Handorf EA, Nikonova A, Dubyk C, Peri S, et al. Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget. 2015 May 29;6:18863-18874. doi:10.18632/oncotarget.4321.
Citation to related work
Impact Journals
Has part
Oncotarget, Vol. 6, No. 22
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu